We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Multiplex Genotyping Developed for Rare Blood Types

By LabMedica International staff writers
Posted on 21 Mar 2013
A multiplex polymerase chain reaction combined with DNA pooling for mass screening has been developed for rare blood types. More...


All existing sequence-specific primers polymerase chain reaction (PCR-SSP) assays for blood typing, genotype one or several single-nucleotide polymorphisms (SNPs) individually, but DNA pooling is a way that reduces the amount of genotyping required.

Scientists at the Shanghai Blood Center (China) established a sensitive multiplex PCR-SSP assay testing pooled DNA to detect the rare Fyb and S alleles. It was applied to screen a total of 4,490 donor samples via testing of 898 DNA pools. The samples in the positive pools were further tested individually. Genomic DNA was extracted from ethylenediaminetetraacetate (EDTA) anticoagulated blood samples using the TIANamp Genomic DNA Kit (Tiangen Biotech; Beijing, China). Every five DNA samples of the 4,490 donors screened were pooled before the multiplex PCR.

Two hundred and fifty-four donors were tested positive for the Duffy Fyb allele, whereas 101 donors were positive for the S allele. Among the 254 Fy(b+) donors, five were Fy(a−b+) and 249 were Fy(a+b+). Among the 101 S+ donors, three were S+s− and 98 were S+s+. The rare Fyb and S alleles comprised 2.28% and 1.16%, respectively. The PCR-SSP assays were confirmed by sequencing analysis and serological testing.

The authors concluded that this genetic high-throughput screening provides a means of detecting relatively large numbers of donors while providing, to a certain extent, antigen-negative blood for “difficult” patients with rare antibodies. The multiplex PCR assay was combined with DNA pooling to reduce the number of tests required, making large-scale screening feasible, and a cost-effective strategy. The study was published on January 22, 2013, in the journal Transfusion Medicine.

Related Links:
Shanghai Blood Center
Tiangen Biotech


New
Gold Member
Automatic Hematology Analyzer
CF9600
New
Gold Member
Neonatal Heel Incision Device
Tenderfoot
New
Japanese Encephalitis Test
Japanese Encephalitis Virus Real Time PCR Kit
New
Electrolyte Analyzer
BKE-B
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Plasma pTau217 testing can predict future amyloid accumulation and cognitive decline in cognitively healthy older adults (photo courtesy of Shutterstock)

Blood Test Predicts Alzheimer Disease Risk Before Imaging Changes and Symptoms

Alzheimer's disease often advances silently for years, making timely risk stratification difficult in routine practice. Current approaches to detect pathology can involve lumbar puncture or positron emission... Read more

Industry

view channel
Image: The GenoPredict assay from Predicta Biosciences is available to Tempus Life Sciences partners to support exploratory research and clinical development programs (photo courtesy of Shutterstock)

Partnership Expands Ultrasensitive WGS Assay for for Hematologic Malignancies and MRD Monitoring

Tempus AI and Predicta Biosciences announced the commercial expansion of a co-branded whole‑genome sequencing assay GenoPredicta, which is intended for comprehensive genomic characterization of hematologic... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.